The pharmaceutical industry continues to experience decreasing productivity and high levels of attrition. Inflation of molecule physicochemical properties and complexities in clinical trial protocols stand among the main reasons for these trends. The most successful companies can leverage different expertise, manage risks, and follow logical sequences of operations in an integrated manner.
This event will focus on key considerations for transitioning a molecule from discovery through clinical studies including molecule developability assessment, phase appropriate formulation selection, integration of product development and clinical supply, and creating an appropriate clinical study design.
Date: March 7, 2019
Time: 9:30 – 15:00
Venue: Medicon Valley Alliance, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen, Denmark, Ground floor
Agenda
9:30 |
Registration & Coffee |
10:00 |
Welcome Will Downie, Senior Vice-President, Catalent Pharma Solutions & |
10:10 |
Assessing Molecule Developability Using Pharmacokinetic Modeling
Jan Neelissen, Scientifc Adviser, Science & Technology, Catalent |
10:55 |
Drug Product
Rob Harris, Chief Technical Officer, Catalent |
11:40 |
Lunch and Networking |
12:30 |
Efficient Coordination of Clinical Supplies
Susie Jelsbak Christensen, Clinical Supply Manager, Symphogen |
13:15 |
Clinical Studies
Gunnar Danielsson, Senior Regulatory Advisor, LINK Medical Research AS |
14:00 |
Closing Remarks Andy Maitland, Account Director, Catalent |
14:10 |
Coffee and Networking |
15:00 |
End of seminar |
Following the meeting, all presenters and Catalent’s Science and Technology leaders will be available for private, no-obligation discussions on specific programmes and challenges.
Organized by: |
In collaboration with: |